Lung cancer drug tabrecta® under Real-World watch in south korea
NCT ID NCT05703516
First seen Jun 16, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This study is for people with non-small-cell lung cancer that has a specific genetic change (exon 14 skipping mutation). It will track how safe and effective the drug Tabrecta® (Capmatinib) is when used in everyday medical practice. About 44 participants will be followed to record side effects and how well the drug shrinks tumors. The goal is to confirm the drug works as expected outside of controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGDaegu, Dalseo gu, 42602, South Korea
-
Novartis Investigative Site
RECRUITINGSuwon, Gyeonggi-do, 16499, South Korea
-
Novartis Investigative Site
RECRUITINGIncheon, Korea, 405 760, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 02447, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06351, South Korea
-
Novartis Investigative Site
RECRUITINGBusan, 602-030, South Korea
-
Novartis Investigative Site
RECRUITINGDaejeon, 302-241, South Korea
-
Novartis Investigative Site
RECRUITINGJeollanam, 519763, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
Conditions
Explore the condition pages connected to this study.